The evidence on whether monoclonal antibodies prevent long COVID is mixed and incomplete. A controlled trial found no significant difference in long COVID symptoms between patients who received monoclonal antibody treatment and those who got a placebo. At the same time, a retrospective study and several dramatic case reports suggest these treatments could reduce risk or even reverse symptoms in some people. The honest answer is that we don’t yet have definitive proof either way, but there are reasons for cautious optimism in specific scenarios.
What Controlled Trials Show
The strongest form of evidence in medicine is a randomized controlled trial, where some patients get the real treatment and others get a placebo. When researchers at Weill Cornell Medicine analyzed this kind of data, they found no significant difference in self-reported long COVID symptoms between the treated and untreated groups. That’s a sobering result for anyone hoping monoclonal antibodies are a straightforward shield against long COVID.
However, one retrospective study from Italy painted a different picture. Researchers matched patients who received early monoclonal antibody or antiviral treatment during acute COVID with similar patients who didn’t, then tracked who developed long COVID afterward. That study found the treated group had lower rates of long-term symptoms. The key difference: this wasn’t a randomized trial, so other factors could have influenced the results.
Why the Theory Makes Sense
Even without ironclad trial data, there’s a logical biological reason monoclonal antibodies might help. One leading theory about long COVID is that fragments of the virus linger in the body long after the initial infection clears. These persistent viral remnants can keep the immune system in a state of low-grade activation, potentially driving ongoing fatigue, brain fog, and other symptoms.
Monoclonal antibodies are designed to latch onto the virus and neutralize it, helping the body clear it more efficiently. If viral persistence is what drives long COVID in at least some patients, then faster, more thorough viral clearance during the acute phase could, in theory, prevent the conditions that lead to chronic symptoms. By reducing the amount of virus and viral debris, these treatments could also calm downstream problems like blood vessel dysfunction, brain inflammation, and immune system overreaction.
The catch is that long COVID likely isn’t one single condition with one single cause. Viral persistence is just one proposed mechanism. Autoimmune responses, nerve damage, and changes to the gut microbiome are others. A treatment targeting viral remnants would only help the subset of patients whose long COVID is driven by that specific problem.
Case Reports of Dramatic Recovery
Some of the most striking evidence comes not from prevention but from treatment of existing long COVID. A case series published in the American Journal of Emergency Medicine described three previously healthy, middle-aged adults who had been severely debilitated by long COVID for months. One had been sick for 18 months, another for 8, and a third for 5. All three suffered from chronic fatigue and cognitive impairment so severe they couldn’t work or exercise normally.
Each received an infusion of the casirivimab/imdevimab cocktail (originally developed to treat acute COVID) and experienced complete remission of their symptoms within a week. They returned to their normal lives and occupations, with full exercise tolerance restored. At the time of publication, those recoveries had been sustained for over two years.
These cases are compelling but come with important caveats. Three patients is an extremely small number, and case reports can’t prove cause and effect. The remissions could have been coincidental, or these individuals may represent a specific subtype of long COVID that responds to antibody treatment while others do not. Still, the speed and completeness of recovery across all three patients caught researchers’ attention and prompted calls for larger studies.
Timing Matters
For monoclonal antibodies to have the best chance of preventing long COVID, timing during the acute infection appears critical. Treatment protocols have generally required administration within 10 days of symptom onset, before the infection progresses to the point of hospitalization or the need for supplemental oxygen. The logic is straightforward: the earlier you neutralize the virus, the less opportunity it has to establish the kind of persistent presence that may drive long-term symptoms.
Patients at highest risk of severe COVID were prioritized for early treatment. This included adults over 65, people with obesity, uncontrolled diabetes, chronic kidney disease, immunodeficiency, cardiovascular disease, or chronic respiratory conditions. Whether the same timing window applies specifically to long COVID prevention remains an open question.
Most Early Antibodies No Longer Work
There’s a practical problem that limits much of this discussion: most monoclonal antibodies developed early in the pandemic have lost their effectiveness against current virus strains. The SARS-CoV-2 virus has evolved significantly since 2020, and the antibodies designed to target the original and early variant spike proteins can no longer latch onto the newer Omicron subvariants.
The FDA pulled authorization for several major treatments as variants rendered them useless. REGEN-COV (the casirivimab/imdevimab cocktail from the case reports above) lost its authorization in January 2022 due to the Omicron variant. Sotrovimab followed in April 2022. Bebtelovimab was pulled in November 2022 because it couldn’t neutralize the BQ.1 and BQ.1.1 subvariants. Laboratory studies have confirmed the pattern: antibodies that powerfully neutralized earlier strains showed a stepwise decline in effectiveness as new variants emerged, with some becoming completely ineffective against XBB and later sublineages.
As of 2024, pemivibart (brand name Pemgarda) received emergency use authorization for COVID-19 prevention in immunocompromised adults. It was designed to work against more recent variants, but it has not been specifically studied or authorized for long COVID prevention. The landscape of available monoclonal antibodies continues to shift as the virus evolves.
Where This Leaves You
If you’re looking for a proven way to prevent long COVID with monoclonal antibodies, the evidence isn’t there yet. The controlled trial data didn’t show a clear benefit, and the most promising results come from small case series and retrospective analyses that can’t establish definitive proof. The biological reasoning is sound for a subset of long COVID cases driven by persistent virus, but that theory hasn’t been validated in large-scale prevention trials.
The practical reality adds another layer of complexity. Most of the antibody treatments that showed early promise are no longer effective against circulating variants, and the newer antibodies haven’t been tested for this specific purpose. Researchers are actively exploring whether next-generation monoclonal antibodies, engineered to work across multiple variants, could fill this gap. For now, vaccination, early antiviral treatment during acute infection, and general risk reduction remain the most broadly supported strategies for lowering long COVID risk.